Madrigal Pharmaceuticals market cap MDGL
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Nov 2, 2026
- $10B
- Highest close in our data
- $13.6B
- Dec 2025
Madrigal Pharmaceuticals is worth $10B at the close on Nov 2, 2026, at $431.16 a share.
That is down 10% over the last year and up 526% over five years.
Its highest close in our data was $13.6B in Dec 2025.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $10B | $9.9B | $13.5B | −27% |
| 2025 | $13.6B | $5.9B | $13.6B | +99% |
| 2024 | $6.8B | $3.7B | $7.6B | +49% |
| 2023 | $4.6B | $2.2B | $5.7B | −8% |
| 2022 | $5B | $964.1M | $5B | +243% |
| 2021 | $1.4B | $1.2B | $2.2B | −16% |
| 2020 | $1.7B | $927.8M | $2B | +20% |
| 2019 | $1.4B | $1.3B | $2.2B | −11% |
| 2018 | $1.6B | $1.2B | $4.3B | +40% |
| 2017 | $1.1B | $169.4M | $1.2B | +565% |
| 2016 | $172.4M | $26.2M | $191.1M | +257% |
| 2015 | $48.2M | $42.7M | $330.7M | −83% |
| 2014 | $284.2M | $284.2M | $445.7M | −17% |
| 2013 | $340.7M | $275.2M | $709.4M | −38% |
| 2012 | $550.3M | $213.8M | $590M | +138% |
| 2011 | $231.2M | $152.4M | $240.6M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Madrigal Pharmaceuticals' size, closest first, today.
| Company | Market cap |
|---|---|
| MDGLMadrigal Pharmaceuticals | $10B |
| TGTXTG Therapeutics | $9.2B |
| PTGXProtagonist Therapeutics | $9B |
| BMRNBiomarin Pharmaceutical | $11.1B |
| CORTCorcept Therapeutics | $8.7B |
| ALKSAlkermes plc. | $7.5B |
| JAZZJazz Pharmaceuticals | $13.9B |
| KNSAKiniksa Pharmaceuticals International | $7.1B |
| AMRXAmneal Pharmaceuticals | $6.5B |
| LGNDLigand Pharmaceuticals | $6.1B |
| INDVIndivior Pharmaceuticals | $4.3B |
| Peer median | $8.1B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Madrigal Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.